z-logo
Premium
Comparison of 60 or 90 mg/m 2 of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics
Author(s) -
Devillier Raynier,
Bertoli Sarah,
Prébet Thomas,
Huguet Françoise,
Etienne Anne,
Charbonnier Aude,
Rey Jérôme,
Delabesse Eric,
D'Incan Evelyne,
Huynh Anne,
Blaise Didier,
Récher Christian,
Vey Norbert
Publication year - 2015
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23884
Subject(s) - daunorubicin , cytogenetics , myeloid leukemia , medicine , leukemia , myeloid , cancer research , biology , genetics , chromosome , gene

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here